These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23883588)

  • 1. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
    Fukuda H; Kubota K; Matsuzawa T
    Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
    Gulyás B; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
    Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
    Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
    No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
    Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
    Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis.
    Kanegae K; Nakano I; Kimura K; Kaji H; Kuge Y; Shiga T; Zhao S; Okamoto S; Tamaki N
    Ann Nucl Med; 2007 Aug; 21(6):331-7. PubMed ID: 17705012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation for performing ¹¹C-methionine and ¹⁸F-FDG-PET studies on the same day.
    Mitsumoto T; Kubota K; Sato T; Morooka M; Minamimoto R; Shimbo T; Muramatsu Y; Sasaki T; Ito K; Fukushi M
    Nucl Med Commun; 2012 Mar; 33(3):297-304. PubMed ID: 22107999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis.
    Ng D; Jacobs M; Mantil J
    Clin Nucl Med; 2006 Jul; 31(7):373-5. PubMed ID: 16785800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography in oncology: the most sophisticated imaging technology.
    Lacić M; Maisey MN; Kusić Z
    Acta Med Croatica; 1997; 51(1):1-9. PubMed ID: 9115096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography.
    Utriainen M; Metsähonkala L; Salmi TT; Utriainen T; Kalimo H; Pihko H; Mäkipernaa A; Harila-Saari A; Jyrkkiö S; Laine J; Någren K; Minn H
    Cancer; 2002 Sep; 95(6):1376-86. PubMed ID: 12216107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of positron emission tomography (PET) in oncology.
    Weber WA; Avril N; Schwaiger M
    Strahlenther Onkol; 1999 Aug; 175(8):356-73. PubMed ID: 10481766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging (PET) of brain tumors.
    Basu S; Alavi A
    Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Kubota K
    Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of metabolic PET imaging in radiation oncology.
    Zhu A; Marcus DM; Shu HK; Shim H
    Radiat Res; 2012 Apr; 177(4):436-48. PubMed ID: 22339451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.